BillionToOne Announces Launch of Initial Public Offering Roadshow

Rhea-AI Summary

BillionToOne (NASDAQ: BLLN) launched the roadshow for a proposed initial public offering of 3,846,000 shares of Class A common stock, with a 30-day underwriter option to purchase up to 576,900 additional shares.

The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker BLLN. J.P. Morgan, Piper Sandler, Jefferies and William Blair are joint book-running managers.

A registration statement on Form S-1 has been filed with the SEC but has not yet become effective; offers or sales may not occur before effectiveness.

Positive

• Proposed IPO of 3,846,000 Class A shares
• Underwriters' 30-day option for 576,900 additional shares
• Expected price range of $49.00 to $55.00 per share
• Planned Nasdaq Global Select listing under ticker BLLN

Negative

• Registration statement not yet effective; securities unsellable
• Underwriter option could increase share count and dilution

Insights

Capital Markets Strategist

BillionToOne launched an IPO roadshow for 3,846,000 Class A shares with a price range of $49.00 to $55.00.

The company, BillionToOne, has begun a roadshow for a proposed initial public offering of 3,846,000 Class A shares and has offered underwriters a 30-day option for up to 576,900 additional shares. The filing seeks to list the Class A common stock on Nasdaq Global Select under the ticker BLLN, with joint book-running managers named as J.P. Morgan, Piper Sandler, Jefferies and William Blair and additional book-runners listed.

Execution depends explicitly on the registration statement becoming effective and on pricing within the stated $49.00–$55.00 range; the release also reiterates that sales cannot occur before effectiveness. Watch whether the registration becomes effective and whether the underwriter option (576,900 shares) is exercised during the 30-day window; these items will determine deal size and near-term supply into the market following the Oct. 29, 2025 announcement.

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 shares of its Class A common stock. In addition, BillionToOne intends to grant the underwriters a 30-day option to purchase up to an additional 576,900 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “BLLN.”

J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers for the proposed offering. Stifel, Wells Fargo Securities and BTIG are also acting as book-running managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

A registration statement on Form S-1 related to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Media Contact
billiontoone@moxiegrouppr.com

FAQ

What size IPO did BillionToOne (BLLN) launch on October 29, 2025?

BillionToOne launched a proposed IPO of 3,846,000 Class A shares with a 30-day option for 576,900 additional shares.

What is the expected price range for BillionToOne (BLLN) shares in the IPO?

The initial public offering price is currently expected to be between $49.00 and $55.00 per share.

Will BillionToOne (BLLN) be listed on Nasdaq after the IPO?

BillionToOne has applied to list Class A common stock on the Nasdaq Global Select Market under the ticker BLLN.

Who are the lead underwriters for BillionToOne's (BLLN) proposed IPO?

J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers.

Can BillionToOne (BLLN) shares be sold immediately following the roadshow?

No; a Form S-1 registration statement has been filed but has not yet become effective, so securities may not be sold before effectiveness.